Neoprobe Introduces Innovative Products At Surgical Meeting

DUBLIN, OHIO (March 5) BW HEALTHWIRE -March 5, 1999--Neoprobe Corporation (Nasdaq/NMS:NEOP) introduced new products at the Society of Surgical Oncology's 52nd Annual Cancer Symposium, March 4-7, 1999 in Orlando, Florida.

The products include three reusable, interchangeable Radel(R) plastic detection probes, and a universal disposable connector. The probes can be used with both the Neoprobe(R) 1500 and neo2000(TM) gamma detection systems for gamma guided surgeries, including intraoperative lymphatic mapping (ILM) for breast cancer and melanoma.

Matthew Bowman, Neoprobe's Senior Vice President of Marketing and Operations, stated, "We are constantly striving to maintain our leadership position in the field of gamma guided surgery. These interchangeable Radel plastic probe tips were designed with the surgeons' needs in mind, and further broadens our product line. The tips represent a breakthrough in design, since they are the first lightweight plastic probes to be introduced to the marketplace."

Richard Orahood, M.D., Neoprobe's Medical Director stated, "The interchangeability and high degree of accuracy of these probes, along with the new neo2000 control unit, provides the highest quality gamma guided surgery system."

The three reusable interchangeable probe tips -- 12mm uncollimated, 12mm collimated and 19mm uncollimated -- use one universal, sterilized, disposable handle and cable. External collimators are available for the uncollimated tips. Surgeons will have the flexibility to change probes and collimators immediately in the sterile operating field.

Small and lightweight, the probes are designed to be easy to maneuver in surgery, yet just as durable as chrome probes. The plastic probes are 70% lighter in weight than competitive probes, and 40% lighter than Neoprobe chrome probes. The probe tips are sterilizable so they can be easily cleaned and quickly used again. The universal handle is pre-sterilized for single use.

All three probe tips, and Neoprobe's 19mm and 14mm chrome probes contain highly sensitive cadmium zinc telluride crystals which detect all common radioisotopes, including Indium-111, Iodine-131, Iodine-125 and Technetium-99m, which is used in ILM surgical procedures.

The statements made in this news release contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from Neoprobe's expectations. In addition to the matters described in this news release, ultimate timing and FDA clearance and other regulatory agencies, inherent uncertainties accompanying new product development and marketing, actions of government and private organizations concerning reimbursement, the impact of competitive products and pricing, the results of further clinical trials as well as the risk factors listed from time to time in Neoprobe's SEC filings, including but not limited to its annual report on Form 10-K for the year ended December 31, 1997, may affect the actual results achieved by Neoprobe.

-0- all/clv*

CONTACT: Neoprobe Corporation

          David Bupp or Myra Miller, 614/793-7500 

E-MAIL: info@neoprobe.com

          HOME PAGE: www.neoprobe.com 

KEYWORD: OHIO FLORIDA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICINE PRODUCT Today's News On The
Net - Business Wire's full file on the Internet

with Hyperlinks to your home page.

                      URL: http://www.businesswire.com